These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24480845)

  • 1. Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
    Imai H; Shukuya T; Yoshino R; Muraki K; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Tomizawa Y; Takahashi T; Takahashi K; Saito R; Yamamoto N
    Chemotherapy; 2013; 59(4):307-13. PubMed ID: 24480845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
    Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
    Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.
    Okuda K; Hirose T; Oki Y; Murata Y; Kusumoto S; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Ohnishi T; Ohmori T
    Anticancer Res; 2012 Dec; 32(12):5475-80. PubMed ID: 23225454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
    Sasidharan R; Gibbs D; Sullivan R; Simpson A; Perez D; Christmas T; McKeage M
    N Z Med J; 2006 Nov; 119(1245):U2310. PubMed ID: 17146485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
    Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
    Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.
    Leon L; Vázquez S; Gracia JM; Casal J; Lazaro M; Firvida JL; Amenedo M; Santome L; Macia S
    Expert Opin Pharmacother; 2012 Jul; 13(10):1389-96. PubMed ID: 22630129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
    Gauthier I; Ding K; Winton T; Shepherd FA; Livingston R; Johnson DH; Rigas JR; Whitehead M; Graham B; Seymour L
    Lung Cancer; 2007 Mar; 55(3):357-63. PubMed ID: 17141357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.
    Kenmotsu H; Ohde Y; Shukuya T; Eida H; Akamatsu H; Ono A; Nakamura Y; Tsuya A; Kaira K; Naito T; Murakami H; Takahashi T; Maniwa T; Isaka M; Endo M; Kondo H; Yamamoto N
    Respir Investig; 2012 Dec; 50(4):157-61. PubMed ID: 23199980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of biweekly chemotherapy with docetaxel and cisplatin in high-risk patients with unresectable non-small cell lung cancer.
    Kim MJ; Kim SH; Kang JH; Kim HG; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim MG; Choi JY; Lee GW
    Chemotherapy; 2013; 59(3):159-66. PubMed ID: 24107481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Beckmann G; Fietkau R; Huber RM; Kleine P; Schmidt M; Semrau S; Aubert D; Fittipaldo A; Flentje M
    Onkologie; 2006 Apr; 29(4):137-42. PubMed ID: 16601369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin plus vinorelbine as induction chemotherapy followed by surgery in the treatment of stage IIIB non-small cell lung cancer. Final results of a multicenter phase II study.
    Cigolari S; Curcio C; Maiorino A; Sessa R; Cioffi A; Massimo M
    Anticancer Res; 2003; 23(2C):1803-9. PubMed ID: 12820462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?
    Provencio M; de Las Peñas R; Camps C; Artal A; Massuti B; Cobo M; Pérez FJ; Sánchez A; Rosell R
    Lung Cancer; 2010 Jun; 68(3):415-9. PubMed ID: 19695734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation.
    Douillard JY; Tribodet H; Aubert D; Shepherd FA; Rosell R; Ding K; Veillard AS; Seymour L; Le Chevalier T; Spiro S; Stephens R; Pignon JP;
    J Thorac Oncol; 2010 Feb; 5(2):220-8. PubMed ID: 20027124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.